How research peptides are regulated around the world

A vial of BPC-157 labeled for research use can be bought online in the United States, the United Kingdom, the European Union, Canada and Australia. In each of those places the vial is the same, the label is the same, and the law that applies to it is different. Five regulators have answered the same question, when a research peptide becomes a medicine, with five definitions, and in the past eighteen months all five have said in public that the words "research use only" on the label do not settle it. This page is the first of a series on how research peptides are regulated outside the United States. It sets out the four questions every system answers, shows how each answers them, and draws out what is the same everywhere. The country pages that follow go into each system in depth.

The four questions every jurisdiction answers about research peptides

1. What makes a peptide a medicine. Every system has a definition of a medicine, and none of them is a list of molecules. The United States asks what the seller intends. The United Kingdom and the European Union ask how the product is presented and what it does. Canada asks what it is represented for. Australia asks what it is represented to be, and then schedules the substance itself. A research peptide crosses the line in each system at a different point, decided by a different kind of evidence.
2. What the research label is worth. Nowhere is a research-use label an exemption. It is a statement about intent or presentation, weighed against everything else the seller says and does. Five regulators have said this in terms since 2025.
3. What happens at the border. Most research peptides are made in Asia, so every system meets them first at customs. The rules for commercial import and personal import differ, and the border is where most enforcement actually happens.
4. Who enforces, and against whom. Medicines regulators, customs services, advertising regulators and professional boards each hold a piece. In every system the actions on the record are against sellers and clinics, not against laboratories buying research peptides for research.

Five systems side by side

How five jurisdictions regulate research peptides, as of November 1, 2026

Jurisdiction	What makes a peptide a medicine	What the research label is worth	At the border	Enforcement on the record, 2025–2026
United States	Intended use, inferred from the seller's statements, the product and the circumstances of sale (FDCA § 201(g); 21 CFR 201.128)	One piece of evidence, weighed against the rest of the site; cited and set aside in every warning letter	Unapproved drugs promoted in the US are detained without examination under Import Alert 66-41; personal import is illegal in most circumstances	Warning letters to research-labeled sellers (see the tracker); eleven manufacturer lawsuits; a federal enforcement-discretion policy for six compounded peptides
United Kingdom	A medicinal product by presentation or by function (Human Medicines Regulations 2012, reg. 2)	No defense against medicinal claims made alongside it; the regulator said so in April 2026	Unlicensed medicines may not be imported for sale; Border Force seizes on the regulator's referral	MHRA investigation of clinics selling "research only" peptides with health claims, opened April 2026
European Union	A medicinal product by presentation or by function (Directive 2001/83/EC, art. 1(2)); in doubt, medicines law prevails (art. 2(2))	Presentation is judged from the whole product, including the vial format and the claims around it	National customs with national medicines agencies; rules differ by member state	By member state; Germany and the Netherlands regard unapproved peptides as unauthorized medicinal products
Canada	Any substance manufactured, sold or represented for use in diagnosis or in modifying organic functions (Food and Drugs Act, s. 2)	Health Canada: research labeling "does not make these products legal or exempt from regulatory requirements"	Health Canada works with the Canada Border Services Agency to stop shipments; a drug needs an eight-digit DIN to be sold	Seizures from online sellers (August 2025), a public advisory naming fourteen peptides (April 2026), a permanent injunction from the Superior Court of Québec (June 2026)
Australia	Goods represented to be, or likely to be taken to be, for use on the body (Therapeutic Goods Act 1989, s. 3), plus scheduling of the substance in the Poisons Standard	Irrelevant to scheduling: BPC-157 is a Schedule 4 substance in Appendix D, so possession without authority is an offense whatever the label says	Import of a Schedule 4 substance needs a prescription under the Personal Importation Scheme; otherwise seized	TGA alerts to importers, compounders and suppliers (April 2026); a coroner's recommendation that the TGA review peptide restrictions (October 2026)

United States: a research peptide is a drug when the seller intends it to be

The American definition turns on intended use. A substance is a drug if it is intended to affect the structure or function of the body, and intent is inferred by the Food and Drug Administration from any relevant source of evidence: the seller's words, the product's design, the circumstances of its sale. The research label is one such source and the rest of the website is the others. Every warning letter to a research-labeled peptide seller on this library's enforcement tracker quotes the disclaimer and then quotes the pages that contradict it. How that inference is made, and why no court reviews it, is the subject of the first five parts of this series and of a perspective piece.

At the border, FDA's Import Alert 66-41 allows unapproved new drugs that are promoted in the United States to be detained without physical examination. Personal importation of a drug is, in the agency's own words, illegal in most circumstances; the exceptions are for a serious condition with no domestic alternative, a product not promoted to Americans, and a three-month supply, none of which describes a research peptide bought online. In 2026 the United States added a layer no other country has: a federal policy that the government will not act against pharmacies compounding six specific peptides, which three state boards had already barred.

United Kingdom: a medicine by presentation or by function

British law copies the European definition. A medicinal product is any substance or combination of substances presented as having properties of preventing or treating disease in human beings, or any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action. The first limb is about what the seller says; the second is about what the substance does. A research peptide with no claims attached is caught, if at all, by the second limb, and the second limb is judged on the substance and its format rather than the label.

In April 2026 a Guardian investigation found clinics in the United Kingdom selling BPC-157, MOTS-c, thymosin alpha-1 and others at several hundred pounds a month, with stated benefits, while labeling them "research only". The Medicines and Healthcare products Regulatory Agency opened an investigation and said: If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012. The MHRA will take action against clinics which are identified as breaching the legal requirements. That is the presentation limb applied to the research label: the claim makes the medicine, and the label does not unmake it.

European Union: one definition, twenty-seven enforcers

Directive 2001/83/EC supplies the definition the United Kingdom kept after leaving. Article 1(2) defines a medicinal product by presentation, presented as having properties for treating or preventing disease in human beings, or by function, a substance which may be used in or administered to human beings to restore, correct or modify physiological functions. Article 2(2) adds the rule that decides borderline cases: In cases of doubt, where a product could be a medicine and could be something else, the provisions of this Directive shall apply. A research chemical that could be a medicine falls under medicines law.

What the directive does not supply is an enforcer. Medicines are authorized and policed nationally, so a research peptide sold across the single market meets the German Arzneimittelgesetz in Germany, the Geneesmiddelenwet and the Inspectie Gezondheidszorg en Jeugd in the Netherlands, and a different customs service at each external border. The Court of Justice has held that a product is a medicine by function only if it has a significant effect on physiological functions at the amounts sold, which is a scientific question a national court has to decide product by product. The EU page in this series takes up Germany and the Netherlands, where the enforcement record is longest.

Canada: represented for use, and no exemption for the label

Canada's Food and Drugs Act defines a drug as any substance or mixture of substances manufactured, sold or represented for use in diagnosis or in restoring, correcting or modifying organic functions in human beings or animals. Representation is the operative word, and Health Canada has made the research question explicit. Its advisory of April 9, 2026 says: Health Canada continues to identify products marketed as 'For Research Use Only – Not for Human Consumption.' This type of labelling does not make these products legal or exempt from regulatory requirements. The same advisory states that Unauthorized drug products are illegal in Canada, that an authorized drug carries an eight-digit Drug Identification Number on its label, and that the department is working with the Canada Border Services Agency to stop unauthorized shipments from entering the country.

The record is the most active of the five. On August 1, 2025 Health Canada announced the seizure of peptide products from an online seller and listed thirty-eight peptides by name, BPC-157, CJC-1295, ipamorelin, TB-500 and GHK among them. On June 11, 2026 the Superior Court of Québec granted a permanent injunction against another online seller, announced in July, barring it from manufacturing, testing, distributing, selling or advertising unapproved peptides. Health Canada's statement with it is one sentence long and leaves no room: In Canada, injectable peptides are regulated as prescription drugs and must be authorized by Health Canada before they can be sold.

Australia: the substance is scheduled, so the label cannot help

Australia is the one system of the five that regulates the molecule rather than the claim. The Therapeutic Goods Act 1989 defines the goods it covers by representation, like Canada, but the Poisons Standard then places individual substances in schedules that control possession and supply regardless of how they are sold. BPC-157 is in Schedule 4, prescription only, and in Appendix D, the list of Schedule 4 substances whose possession without authority is itself an offense. A research-labeled vial of BPC-157 in Australia is therefore not a chemical with an ambiguous label. It is a scheduled substance, and the only question is whether the person holding it has authority to.

The Therapeutic Goods Administration's alerts of April 2026, to importers, compounders and suppliers of unapproved peptide products, named BPC-157, GHK-Cu, TB-500 and CJC-1295 and warned that promoting them, particularly through social media or influencer channels, is likely to breach Australian therapeutic goods advertising laws. Import for personal use is allowed only under the Personal Importation Scheme, which for a Schedule 4 substance requires a prescription; otherwise the parcel is seized. On October 28, 2026 the Coroners Court of Victoria asked the TGA to review the therapeutic benefits and safety risks of peptides such as CJC1295 and Ipamorelin and to consider whether further restrictions ought to be imposed on their use, after the first confirmed peptide death in the country. The direction of travel in Australia is toward more scheduling, not less.

Sport: the list that most people meet first

The World Anti-Doping Agency is not a regulator of commerce, but its Prohibited List is where many people first encounter the names of research peptides, and customs officers and journalists read it. The 2026 list, in force from January 1, 2026, prohibits at all times under class S0 any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use, and names BPC-157 as its first example. CJC-1295, ipamorelin, the growth-hormone-releasing peptides and TB-500 are named under S2. A peptide on the list is prohibited for athletes in tested sport everywhere, which is the one rule in this field that does not change at a border.

The source: where research peptides come from

Most of the peptide material sold for research in all five jurisdictions is synthesized in China, where the manufacturer is regulated by the NMPA, China's medicines regulator, only if it makes drugs for the Chinese market. A peptide leaving China as a chemical is a chemical to Chinese customs, and becomes a medicine, or not, under the law of the country it arrives in. That is why the border is the choke point in every system above, and why a certificate of analysis from a manufacturer is the only document that travels with the material across all of them. What that certificate can and cannot show is the subject of the methods series; the page in this series on China covers what a manufacturer's registration means and does not mean.

What is the same everywhere

• The label describes intent; it never creates an exemption. The United States weighs it as evidence. The United Kingdom and the EU look past it to the claim and the function. Canada says in terms that it changes nothing. Australia schedules the substance beneath it. Five systems, one answer.
• The claim makes the medicine. In every enforcement action on the record, the seller or clinic said what the peptide would do. The MHRA investigation, the Health Canada advisories, the Québec injunction, the TGA alert and every FDA warning letter turn on claims, formats and pricing by the course, not on the sale of a labeled chemical to a laboratory.
• The format is evidence. A single-use vial with a syringe-sized volume is read, in every system, as presentation for use in the body. The TGA, Health Canada and the MHRA all describe the products they act against by their format first.
• The border is where the law is applied. Import alerts, Border Force referrals, CBSA cooperation and the Personal Importation Scheme are the instruments that actually stop research peptides. Enforcement inside a country is slower and rarer.
• Laboratories are not the target. No action in any of the five systems since 2023 has been taken against a laboratory buying research peptides for research. The research-use line is enforced against those who cross it, and it is the same line in all five.

What to watch

• The outcome of the MHRA investigation, and whether it produces the United Kingdom's first prosecutions over research-labeled peptides.
• Whether the TGA acts on the coroner's recommendation by scheduling more peptides, or by moving BPC-157 and others further up the schedules.
• Health Canada's next injunction, and whether the department begins acting against buyers as well as sellers.
• Whether any EU member state follows the United Kingdom into a public investigation of clinics.
• Whether the American enforcement-discretion policy for six compounded peptides is copied, cited or rejected by any regulator abroad.

Frequently asked questions

Are research peptides legal in the United Kingdom?

A peptide sold with no medicinal claims and no presentation for use in the body is not, on its face, a medicinal product under the Human Medicines Regulations 2012. A peptide sold with claims about what it does is a medicine by presentation, and an unlicensed one. The MHRA said in April 2026 that labeling a product "research only" does not change that.

Are research peptides legal in Canada?

Health Canada's position is that peptides sold in vial form are prescription drugs that must be authorized before sale, that unauthorized drugs are illegal in Canada, and that research labeling does not exempt them. Its actions have been against online sellers.

Are research peptides legal in Australia?

It depends on the substance, not the label. BPC-157 is a Schedule 4 substance in Appendix D of the Poisons Standard, so possession without authority is an offense. Other peptides are scheduled differently or not at all. Importing a Schedule 4 substance for personal use requires a prescription.

Are research peptides legal in the European Union?

The Directive defines a medicine by presentation or by function, and in doubtful cases medicines law applies. Whether a particular research peptide is a medicine by function is decided nationally, product by product. Enforcement is by each member state's medicines agency and customs.

Does "not for human consumption" on the label protect an importer?

In none of the five systems. FDA weighs it as one piece of evidence. Health Canada says it does not make the product legal. The MHRA says claims alongside it make the product a medicine. In Australia a scheduled substance is scheduled whatever the label says.

Who is actually prosecuted?

On the public record in all five systems: online sellers, clinics and compounders who sold or promoted research-labeled peptides for use in people. No laboratory buying peptides for research appears in any of the actions cited on this page.

Sources & Further Reading

1. Federal Food, Drug, and Cosmetic Act § 201(g)(1), 21 U.S.C. § 321(g)(1); 21 CFR 201.128 (intended use); Food and Drug Administration, Import Alert 66-41, "Detention Without Physical Examination of Unapproved New Drugs Promoted in the U.S."; FDA, "Personal Importation", fda.gov, current as of August 18, 2025.
2. The Human Medicines Regulations 2012, SI 2012/1916, regulation 2(1), definition of "medicinal product".
3. Aesthetics Journal, "MHRA investigates clinics following peptide claims", April 15, 2026, quoting the MHRA statement; The Guardian, "Medicines watchdog to investigate UK peptide clinics over health claims", April 4, 2026.
4. Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, Articles 1(2) and 2(2).
5. Food and Drugs Act, R.S.C. 1985, c. F-27, section 2, definition of "drug".
6. Health Canada, public advisory, Unauthorized injectable peptide drugs seized and sold by [an online seller] may pose serious health risks, August 1, 2025; public advisory, Think twice before injecting peptides bought online: unauthorized products can seriously harm you, April 9, 2026; news release, Health Canada obtains permanent injunction preventing [an online seller]'s illegal sale of injectable peptides in Canada, July 29, 2026 (Superior Court of Québec, June 11, 2026).
7. Therapeutic Goods Act 1989 (Cth), section 3; Poisons Standard (SUSMP), Schedule 4 and Appendix D; Sport Integrity Australia, substance entry for BPC-157.
8. Therapeutic Goods Administration, safety alerts: "Understanding your responsibilities when importing, compounding and supplying unapproved peptide products" and "TGA warning: risks of importing unapproved peptide products", April 2026, as reported by newsGP (RACGP) and Pharmacy Daily, April 14, 2026.
9. Coroners Court of Victoria, findings into the death of Richard Norton, October 28, 2026; see this library's piece.
10. World Anti-Doping Agency, The Prohibited List 2026, in force January 1, 2026, classes S0 and S2.

Cosmic Peptides. (2026, November 1). How research peptides are regulated around the world. Cosmic Peptides Research Library. Retrieved November 1, 2026, from https://cosmicpeptides.com/research/compliance/how-research-peptides-are-regulated-around-the-world

@misc{cosmicpeptides_research_compliance_how_research_peptides_are_regulated_around_the_world,
  author       = {{Cosmic Peptides}},
  title        = {How research peptides are regulated around the world},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/compliance/how-research-peptides-are-regulated-around-the-world},
  urldate      = {2026-11-01},
  note         = {Last reviewed 2026-11-01}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - How research peptides are regulated around the world
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/01
UR  - https://cosmicpeptides.com/research/compliance/how-research-peptides-are-regulated-around-the-world
Y2  - 2026/11/01
LA  - en
ER  -